Tailong Pharmaceutical announced that it recently received a new “Pharmaceutical Production License” from the Henan Drug Administration, which is valid until December 31, 2030. This change includes the scope of production, production lines, and contract conditions. For example, to resume production of some products, it is necessary to apply for drug GMP compliance inspection; reduction of compounds, 9 APIs and corresponding production lines in Zhulin Town, Gongyi City; and reduction of 3 types of drugs, including contract production of berberine hydrochloride tablets. The issuance of a new license ensures the normal operation of the company. It has no significant impact on the current production structure, nor does it affect current performance. However, there is uncertainty about drug production and sales being affected by policies and markets.

Tailong Pharmaceutical announced that it recently received a new “Pharmaceutical Production License” from the Henan Drug Administration, which is valid until December 31, 2030. This change includes the scope of production, production lines, and contract conditions. For example, to resume production of some products, it is necessary to apply for drug GMP compliance inspection; reduction of compounds, 9 APIs and corresponding production lines in Zhulin Town, Gongyi City; and reduction of 3 types of drugs, including contract production of berberine hydrochloride tablets. The issuance of a new license ensures the normal operation of the company. It has no significant impact on the current production structure, nor does it affect current performance. However, there is uncertainty about drug production and sales being affected by policies and markets.